Your browser doesn't support javascript.
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu, Purushothaman; Rameshkumar, Marimuthu Ragavan; Arunagirinathan, Narasingam; Al-Dhabi, Naif Abdullah; Valan Arasu, Mariadhas; Ignacimuthu, Savarimuthu.
  • Indu P; Department of Microbiology and Biotechnology, Presidency College (Autonomous), Affiliated to University of Madras, Chennai, India.
  • Rameshkumar MR; Laboratory Division, ICMR-National Institute of Epidemiology, Chennai, India. Electronic address: rameshmicrobiologist@gmail.com.
  • Arunagirinathan N; Department of Microbiology and Biotechnology, Presidency College (Autonomous), Affiliated to University of Madras, Chennai, India; Central Research Laboratory, Meenakshi Academy of Higher Education and Research (Deemed to be University), Chennai, India.
  • Al-Dhabi NA; Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
  • Valan Arasu M; Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia; Xavier Research Foundation, St. Xavier's College, Palayamkottai, Thirunelveli, Tamilandu, India.
  • Ignacimuthu S; Xavier Research Foundation, St. Xavier's College, Palayamkottai, Thirunelveli, Tamilandu, India.
J Infect Public Health ; 13(12): 1856-1861, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-1023653
ABSTRACT

BACKGROUND:

Outbreak of COVID-19 has been recognized as a global health concern since it causes high rates of morbidity and mortality. No specific antiviral drugs are available for the treatment of COVID-19 till date. Drug repurposing strategy helps to find out the drugs for COVID-19 treatment from existing FDA approved antiviral drugs. In this study, FDA approved small molecule antiviral drugs were repurposed against the major viral proteins of SARS-CoV-2.

METHODS:

The 3D structures of FDA approved small molecule antiviral drugs were retrieved from PubChem. Virtual screening was performed to find out the lead antiviral drug molecules against main protease (Mpro) and RNA-dependent RNA polymerase (RdRp) using COVID-19 Docking Server. Furthermore, lead molecules were individually docked against protein targets using AutoDock 4.0.1 software and their drug-likeness and ADMET properties were evaluated.

RESULTS:

Out of 65 FDA approved small molecule antiviral drugs screened, Raltegravir showed highest interaction energy value of -9 kcal/mol against Mpro of SARS-CoV-2 and Indinavir, Tipranavir, and Pibrentasvir exhibited a binding energy value of ≥-8 kcal/mol. Similarly Indinavir showed the highest binding energy of -11.5 kcal/mol against the target protein RdRp and Dolutegravir, Elbasvir, Tipranavir, Taltegravir, Grazoprevir, Daclatasvir, Glecaprevir, Ledipasvir, Pibrentasvir and Velpatasvir showed a binding energy value in range from -8 to -11.2 kcal/mol. The antiviral drugs Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine also exhibited good bioavailability and drug-likeness properties.

CONCLUSION:

This study suggests that the screened small molecule antiviral drugs Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine could serve as potential drugs for the treatment of COVID-19 with further validation studies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / RNA-Dependent RNA Polymerase / Coronavirus Protease Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2020 Document Type: Article Affiliation country: J.jiph.2020.10.015

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / RNA-Dependent RNA Polymerase / Coronavirus Protease Inhibitors / SARS-CoV-2 / COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study Limits: Humans Language: English Journal: J Infect Public Health Journal subject: Communicable Diseases / Public Health Year: 2020 Document Type: Article Affiliation country: J.jiph.2020.10.015